CN107259576A - Probiotic composition for being good for intestines - Google Patents
Probiotic composition for being good for intestines Download PDFInfo
- Publication number
- CN107259576A CN107259576A CN201710415773.XA CN201710415773A CN107259576A CN 107259576 A CN107259576 A CN 107259576A CN 201710415773 A CN201710415773 A CN 201710415773A CN 107259576 A CN107259576 A CN 107259576A
- Authority
- CN
- China
- Prior art keywords
- probiotic composition
- parts
- lactobacillus
- intestines
- bifidobacterium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000006041 probiotic Substances 0.000 title claims abstract description 84
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 84
- 239000000203 mixture Substances 0.000 title claims abstract description 83
- 230000000529 probiotic effect Effects 0.000 title claims abstract description 83
- 210000000936 intestine Anatomy 0.000 title claims abstract description 22
- 241000186000 Bifidobacterium Species 0.000 claims abstract description 23
- 241000186660 Lactobacillus Species 0.000 claims abstract description 21
- 229940039696 lactobacillus Drugs 0.000 claims abstract description 20
- 239000000843 powder Substances 0.000 claims abstract description 12
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 claims abstract description 10
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 claims abstract description 8
- 235000013325 dietary fiber Nutrition 0.000 claims abstract description 8
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 claims abstract description 8
- 229920002774 Maltodextrin Polymers 0.000 claims abstract description 7
- 229920001100 Polydextrose Polymers 0.000 claims abstract description 7
- 235000013856 polydextrose Nutrition 0.000 claims abstract description 7
- 240000002319 Citrus sinensis Species 0.000 claims abstract description 6
- 235000005976 Citrus sinensis Nutrition 0.000 claims abstract description 6
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims abstract description 6
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims abstract description 6
- 235000009685 Crataegus X maligna Nutrition 0.000 claims abstract description 6
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims abstract description 6
- 235000009486 Crataegus bullatus Nutrition 0.000 claims abstract description 6
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims abstract description 6
- 235000009682 Crataegus limnophila Nutrition 0.000 claims abstract description 6
- 235000004423 Crataegus monogyna Nutrition 0.000 claims abstract description 6
- 235000002313 Crataegus paludosa Nutrition 0.000 claims abstract description 6
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims abstract description 6
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 6
- 239000005913 Maltodextrin Substances 0.000 claims abstract description 5
- 229940035034 maltodextrin Drugs 0.000 claims abstract description 5
- 229940035035 polydextrose Drugs 0.000 claims abstract description 5
- 239000001259 polydextrose Substances 0.000 claims abstract description 5
- 239000003085 diluting agent Substances 0.000 claims abstract description 4
- -1 oligoisomaltose Substances 0.000 claims abstract description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims abstract description 3
- 240000000171 Crataegus monogyna Species 0.000 claims abstract 2
- 241000894006 Bacteria Species 0.000 claims description 16
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims description 9
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims description 7
- 229940009289 bifidobacterium lactis Drugs 0.000 claims description 7
- 241000186012 Bifidobacterium breve Species 0.000 claims description 6
- 241000186604 Lactobacillus reuteri Species 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 6
- 229940001882 lactobacillus reuteri Drugs 0.000 claims description 6
- 230000002779 inactivation Effects 0.000 claims description 2
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 claims 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 claims 1
- 206010010774 Constipation Diseases 0.000 abstract description 31
- 244000052616 bacterial pathogen Species 0.000 abstract description 7
- 230000008944 intestinal immunity Effects 0.000 abstract description 6
- 208000005016 Intestinal Neoplasms Diseases 0.000 abstract description 5
- 201000002313 intestinal cancer Diseases 0.000 abstract description 5
- 206010028980 Neoplasm Diseases 0.000 abstract description 3
- 238000006243 chemical reaction Methods 0.000 abstract description 3
- 230000000968 intestinal effect Effects 0.000 abstract description 3
- 230000008384 membrane barrier Effects 0.000 abstract description 3
- 210000004400 mucous membrane Anatomy 0.000 abstract description 3
- 206010012735 Diarrhoea Diseases 0.000 description 16
- 230000013872 defecation Effects 0.000 description 16
- 230000002354 daily effect Effects 0.000 description 14
- 230000035611 feeding Effects 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 238000010586 diagram Methods 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 230000002550 fecal effect Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 206010027654 Allergic conditions Diseases 0.000 description 6
- 108010074328 Interferon-gamma Proteins 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 208000026935 allergic disease Diseases 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 241001092040 Crataegus Species 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 230000009610 hypersensitivity Effects 0.000 description 4
- 229940099472 immunoglobulin a Drugs 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 102100037850 Interferon gamma Human genes 0.000 description 3
- 102000008070 Interferon-gamma Human genes 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 229960003130 interferon gamma Drugs 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 241000186016 Bifidobacterium bifidum Species 0.000 description 2
- 241000193403 Clostridium Species 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 206010022678 Intestinal infections Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000000711 cancerogenic effect Effects 0.000 description 2
- 231100000315 carcinogenic Toxicity 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000369 enteropathogenic effect Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000030136 gastric emptying Effects 0.000 description 2
- 230000005176 gastrointestinal motility Effects 0.000 description 2
- 230000002650 habitual effect Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 230000008855 peristalsis Effects 0.000 description 2
- 208000015768 polyposis Diseases 0.000 description 2
- 235000013406 prebiotics Nutrition 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000220324 Pyrus Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000021017 pears Nutrition 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/01—Instant products; Powders; Flakes; Granules
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/717—Celluloses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/173—Reuteri
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/175—Rhamnosus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/515—Animalis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/519—Breve
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/531—Lactis
Abstract
The present invention provides a kind of probiotic composition of strong intestines, the probiotic composition includes lactobacillus, Bifidobacterium, sweet orange Fruit powder, hawthorn powder, oligoisomaltose, maltodextrin, polydextrose, dietary fiber, stachyose, D-sorbite, and physiologically acceptable excipient and/or diluent.The probiotic composition that the present invention is provided can effective relief of constipation；Protection and stable mucous membrane barrier, are obstructed or from the intrusion of enteric pathogenic bacteria；Prevent the possibility that intestinal cancer occurs or intestinal canal tumour grows；Stimulate and adjust intestine immunity reaction.
Description
Technical field
The invention belongs to technical field of food science, more particularly to a kind of probiotic composition for being used to be good for intestines.
Background technology
In the modern life, the work rhythm of people is accelerated, and under hard work pressure, people often form some not
Good habits and customs, for example, long-time sitting, less carry out outdoor exercises, diet are irregular, excessive drinking etc., it is above-mentioned not
Good habits and customs and operating pressure, easily cause the various intestines problems bothered.
Enteron aisle is not only digestive organs, even more human body most powerful immune organ, is the second brain --- abdomen brain, various intestines
Tract disease, for example.Diarrhoea, constipation, intestinal immunity reduction etc. cause greatly pain and puzzlement to the health of people.
It is therefore desirable to develop a kind of good effect, commercialization be used for be good for the probiotic compositions of intestines.
The content of the invention
The technical problems to be solved by the invention are to overcome the shortcomings of to mention with defect that there is provided one in background above technology
Plant good effect, the probiotic composition for being used to be good for intestines of commercialization.
In order to solve the above technical problems, technical scheme proposed by the present invention is a kind of probiotic composition for being used to be good for intestines,
The probiotic composition comprising lactobacillus, Bifidobacterium, sweet orange Fruit powder, hawthorn powder, oligoisomaltose, maltodextrin,
Polydextrose, dietary fiber, stachyose, D-sorbite, and physiologically acceptable excipient and/or diluent.
Preferably, the probiotic composition includes the component of following parts by weight：100-150 parts of lactobacillus, 100-150 parts
Bifidobacterium, 8-10 part oligoisomaltose, 20-30 portions of maltodextrins, 12-14 portions of polydextroses, 25-36 portions of meals are fine
Dimension, 3-7 parts of stachyoses, 4-7 parts of D-sorbites.
Preferably, the lactobacillus includes Lactobacillus rhamnosus and lactobacillus reuteri, and it is double that the Bifidobacterium includes breast
Discrimination bacillus, animal bifidobacteria and bifidobacterium breve.
Preferably, the lactobacillus includes the component of following parts by weight：70-90 parts of Lactobacillus rhamnosus, 60-80 parts of Roys
Family name's lactobacillus.
Preferably, the Bifidobacterium includes the component of following parts by weight：50-60 portions of bifidobacterium lactis, 20-30 portions of animals
Bifidobacterium, 5-10 part bifidobacterium breve.
Preferably, the probiotic composition is inactivation lyophilised state.
Compared with prior art, the advantage of the invention is that：
The probiotic composition can effective relief of constipation；Protection and stable mucous membrane barrier, are obstructed or from enteropathogenic
The intrusion of bacterium；Treat infectiousness diarrhea；Prevent the possibility that intestinal cancer occurs or intestinal canal tumour grows；Stimulate and adjust intestine immunity
Reaction；
Wherein, sweet orange Fruit powder and hawthorn powder can promote gastrointestinal motility, reduce constipation, while being conducive to improving prebiotic
The taste of bacteria composition；
Oligoisomaltose can promote the propagation of lactobacillus and Bifidobacterium, particularly promote the propagation of Bifidobacterium,
The taste of probiotic composition can be adjusted simultaneously；
Stachyose has extremely obvious proliferation function to profitable strains such as Bifidobacterium, lactobacillus, can improve human body rapidly
Environment in alimentary canal, adjusts Tiny ecosystem colony balance.It can promote to form dominant bacteria status of the beneficial bacterium in alimentary canal, suppress
The production of the spoilage organisms such as the sour clostridium of aerogenesis production, produces a large amount of physiological activators in addition, adjusts gut pH, kills
Pathogenic bacteria, check spoilage product generation, suppress endogenous carcinogenic generation and absorption, and decomposition derives Multiple immunizations function
The factor, while stachyose band is pleasantly sweet, can adjust the taste of probiotic composition；
Dietary fiber can effectively reduce the incidences of disease such as intestinal cancer, constipation, polyposis intestinalis；
Lactobacillus and Bifidobacterium can suppress pathogenic bacteria and colonize, the organic acid such as acetic acid and lactic acid produced by newborn Bifidobacterium Bifidum
Gastric emptying can be promoted, promote intestines peristalsis, moisture in excrement is improved, reduction intestines retardance makes habitual constipation patient's defecation
Situation that is normal and relaxing constipation；Lactobacillus rhamnosus can stimulate IgA (immunoglobulin A) to secrete, increase intestine immunity protection
Ability, excludes or displacement enteric pathogenic bacteria, reduces enteric infection probability, can effectively repair impaired gut barrier；Luo Yishi bars
Bacterium can reduce the secretion of IgE (immunoglobulin E), so as to slow down the generation of allergic symptom.
Brief description of the drawings
In order to illustrate more clearly about the embodiment of the present invention or technical scheme of the prior art, below will be to embodiment or existing
There is the accompanying drawing used required in technology description to be briefly described, it should be apparent that, drawings in the following description are the present invention
Some embodiments, for those of ordinary skill in the art, on the premise of not paying creative work, can also basis
These accompanying drawings obtain other accompanying drawings.
Fig. 1 is the averagely daily defecation frequency column of probiotic composition that diarrhea patient takes a preferred embodiment of the present invention
Figure；
Fig. 2 is the averagely daily defecation frequency decline of probiotic composition that diarrhea patient takes a preferred embodiment of the present invention
Number ratio bar graphs；
Fig. 3 is 2 points of the probiotic composition fecal character fraction increase that diarrhea patient takes a preferred embodiment of the present invention
Number ratio bar graphs；
Fig. 4 is the column for the overall severity of probiotic composition constipation that constipation patient takes a preferred embodiment of the present invention
Figure；
Fig. 5 is the column for the probiotic composition straining at stool severity that constipation patient takes a preferred embodiment of the present invention
Figure；
Fig. 6 disturbs for the probiotic composition co-incubation of mouse boosting cell and a preferred embodiment of the present invention after 48 hours
The block diagram of element-γ contents；
After Fig. 7 is the probiotic composition feeding mouse of a preferred embodiment of the present invention, Mice Body internal specific antibody IgE
Detection block diagram；
After Fig. 8 is the probiotic composition feeding mouse of a preferred embodiment of the present invention, Mice Body internal specific antibody
IgG1 detection block diagram；
Fig. 9 is the block diagram of the probiotic composition clinical effective rate of a preferred embodiment of the present invention；
Figure 10 takes the allergic condition incidence of disease post of Patients Before And After for the probiotic composition of a preferred embodiment of the present invention
Shape figure.
Embodiment
For the ease of understanding the present invention, more complete is made to the present invention below in conjunction with Figure of description and preferred embodiment
Face, meticulously describe, but protection scope of the present invention is not limited to embodiment in detail below.
Unless otherwise defined, the implication that all technical terms used hereinafter are generally understood that with those skilled in the art
It is identical.Technical term used herein is intended merely to describe the purpose of specific embodiment, is not intended to the limitation present invention
Protection domain.
Unless otherwise specified, various raw material, reagent, instrument and equipment used in the present invention etc. can be by city
Field is commercially available or can prepared by existing method.
The present invention provides a kind of probiotic composition for being used to be good for intestines.The probiotic composition includes lactobacillus, bifid
Bacillus, sweet orange Fruit powder, hawthorn powder, oligoisomaltose, maltodextrin, polydextrose, dietary fiber, stachyose, sorbose
Alcohol, and physiologically acceptable excipient and/or diluent.
Specifically, the probiotic composition includes the component of following parts by weight：130 parts of lactobacillus, 140 parts of bifid bars
Bacterium, 10 parts of oligoisomaltoses, 24 parts of maltodextrins, 12 parts of polydextroses, 31 parts of dietary fibers, 7 parts of stachyoses, 5 parts of mountains
Pears sugar alcohol.
The lactobacillus include Lactobacillus rhamnosus and lactobacillus reuteri, the Bifidobacterium include bifidobacterium lactis,
Animal bifidobacteria and bifidobacterium breve.
Specifically, the lactobacillus includes the component of following parts by weight：80 parts of Lactobacillus rhamnosus, the newborn bars of 70 parts of Luo Yishi
Bacterium.
Preferably, the Bifidobacterium includes the component of following parts by weight：55 parts of bifidobacterium lactis, 25 parts of animal bifid bars
Bacterium, 8 parts of bifidobacterium breves.
Checking test 1：
Investigation eats influence of the probiotic composition to diarrhea patient.Arrange less than 10 years old；Daily diarrhoea number of times surpasses
Cross 3 times；Diarrhoea days are no more than the patient 54 of 2 days.Observe and count the daily defecation frequency of patient；The change of fecal character.
Severe malnutrition or patient with chronic disease or immunological incompetence are not contained in wherein 54 patients or is suffered from emergency and severe disease
Person, for example, meningitis, pneumonia.
Specifically used following experimental procedure：
1. arranging 54 patients, probiotic composition 12g is taken before sleeping for each person every day, number of days is taken 7-14 days；
2. observing and counting the defecation situation of 54 patients, specifically include averagely daily defecation frequency, defecation frequency and decline
Number, fecal character scoring etc..Wherein, fecal character standards of grading such as table 1 below：
| Fraction | Properties and characteristicses |
| 1 | Granular, hard body |
| 2 | It is intestines shape, bittiness |
| 3 | There is crackle on intestines shape, surface |
| 4 | It is strip, smooth and soft |
| 5 | Slices, but have clear boundary, softness |
| 6 | Fluffy fritter is in scalariform |
| 7 | Liquid, no solids |
Table 1, fecal character grade form
Referring to Fig. 1, Fig. 1 is averagely arranged daily for the probiotic composition that diarrhea patient takes a preferred embodiment of the present invention
Bowel frequency number block diagram.Probiotic composition is not taken in expression in wherein " the 0th day ", and diarrhea patient can be observed by Fig. 1 arranges daily
Bowel frequency number progressively reduced, to medication the 4th day, and average daily defecation frequency is only 1.61 times, it was demonstrated that takes probiotic composition and delays
Solution diarrhoea has good effect.
Referring to Fig. 2, declining for the probiotic composition defecation frequency that diarrhea patient takes a preferred embodiment of the present invention
Number ratio bar graphs.Probiotic composition is not taken in expression in wherein " the 0th day ", can be observed under diarrhea patient defecation frequency
The number ratio of drop is incrementally increased, and to medication the 4th day, the number ratio that defecation frequency declines was up to 100%.
Referring to Fig. 3, taking the probiotic composition fecal character fraction of a preferred embodiment of the present invention for diarrhea patient
The number ratio bar graphs of 2 points of increase.Can be observed diarrhea patient fecal character fraction increase by 2 points number ratio progressively on
Rise, reach within the 1st day 52%, reach 60% within the 3rd day, until reaching 92% on the 5th day.
From the every testing result tested, the probiotic composition can effectively alleviate diarrhoea.
Checking test 2：
Influence of the probiotic composition to the patient with constipation symptom is investigated, arranges weekly defecation frequency to be less than 3
Secondary, difficult defecation, defecate stiff or slight involuntary patient oozed just 39.
Specifically used following experimental procedure：
1. arranging 39 patients to take probiotic composition 12g before sleeping for each person every day, continuously take 4 weeks, during which do not take
The medicine of other treatment constipation；
2. the constipation situation of 39 patients of detection statistics.
Referring to Fig. 4, the probiotic composition entirety severity of a preferred embodiment of the present invention is taken for constipation patient
Block diagram.It is specific to be scored using constipation marking scales (onstipation assessment scale, CAS).Wherein, W0 is to make
With preceding overall Severity of Constipation；W2 is using overall Severity of Constipation after 2 weeks；W4 is serious using overall constipation after 4 weeks
Degree.The overall constipation degree that constipation patient can be observed progressively is declining, and eats before probiotic composition, its overall constipation journey
Spend for 11.81, eat the 2nd week after probiotic composition, overall constipation degree is down to 8.09, after edible probiotic composition
4th week, overall constipation degree was down to 6.36.
Referring to Fig. 5, taking front and rear constipation patient straining at stool for the probiotic composition of a preferred embodiment of the present invention
The block diagram of severity.Specifically, seldom firmly remembering 1 point, 2 points are firmly remembered once in a while, 3 points is often firmly remembered, averages.Its
In, W0 is to use the preceding straining at stool order of severity；W2 is to use the straining at stool order of severity after 2 weeks；W4 is to use defecation after 4 weeks
The firmly order of severity.Constipation patient straining at stool severity can be observed to gradually reduce, eats before probiotic composition, its defecation
Firmly the order of severity is 2.90；Edible probiotic composition the 2nd week, the straining at stool order of severity is 2.18；Edible probiotic group
Compound the 4th week, straining at stool severity is 1.86.
From the every testing result tested, the probiotic composition has good effect for reducing constipation.
Checking test 3：
Use following experimental procedure：
1. 100 mouse are divided into 5 experimental groups, wherein every group 20, experimental group A feedings Lactobacillus rhamnosus, experiment
Group B group feeding Bifidobacterium lactis strains, probiotic composition described in experimental group C feedings, D groups are lactobacillus reuteri, and E groups are the moon
Property control group, the starch of the corresponding grams of feeding.Continuous feeding 30 days；
2. pair mouse carries out breathing experiment, after 24 hours, the content of measurement spleen interferon gamma (IFN-γ)；
3. spleen is put into after being smashed in cushioning liquid, 100g is centrifuged 5 minutes, takes supernatant standby.
4. take the blood cell separating liquid (Ficoll-paque) of equal proportion and spleen cell supernatant and blood 18-20 DEG C with
400g is centrifuged 30-40 minutes.
5. spleen cell layer is taken, after cushioning liquid cleaning cell 2-3 times, with appropriate culture medium (such as RPMI-1640)
Suspension cell.
6. by cell and each experimental group material of 3 days has been activated with 1: 10 ratio co-incubation 48 hours.
7. collect the supernatant of cell culture.Interferon gamma is detected in supernatant using enzyme-linked immunosorbent assay (ELISA)
In content.
Referring to Fig. 6, being the content post of interferon-γ after mouse boosting cell and probiotic composition co-incubation 48 hours
Shape figure.Wherein, the concentration of the IFN-γ in C groups, hence it is evident that higher than experimental group A, B, up to 15000pg/ml, wherein, negative control group
IFN-Y concentration be 0.The secretion of IFN-γ can effectively be increased by proving the probiotic composition that provides of the present invention, and compared to
Single use Lactobacillus rhamnosus, bifidobacterium lactis, lactobacillus reuteri effect are more.
Checking test 4：
Feeding is carried out to mouse using the probiotic composition of different bacterium colony Particle densities, Mice Body specificity is then detected
The content of antibody IgE and internal specific IgG antibody 1.
Referring to Fig. 7, after for the probiotic composition feeding mouse of a preferred embodiment of the present invention, Mice Body internal specific
The detection block diagram of antibody IgE.Wherein, 0.5X:About human body daily contains effective clump count 1*109CFU probiotic group
Compound；1x:About human body daily contains effective clump count 2*109CFU probiotic composition；5X:About human body is daily
Effective clump count 1*1010CFU probiotic composition；P is 2500ng/ml specificity antibody IgE；N is negative control, feeding
Mouse starch.As seen from the figure, the probiotic composition that the edible present invention is provided can reduce the secretion of specificity antibody IgE, and
The secretion of the probiotic composition of IX dosage and the probiotic composition of 5X dosage on IgE influences little.
Referring to Fig. 8, after for the probiotic composition feeding mouse of a preferred embodiment of the present invention, Mice Body internal specific
The detection block diagram of IgG antibody 1；Wherein, 0.5X:About human body daily contains effective clump count 1*109CFU probiotic group
Compound；1x:About human body daily contains effective clump count 2*109CFU probiotic composition；5X:About human body is daily
Effective clump count 1*1010CFU probiotic composition；P is 1500000ng/ml specific antibody IgG1IgE；N is negative right
According to feeding mouse starch.As seen from the figure, the probiotic composition that the edible present invention is provided can reduce specific antibody IgG1 point
Secrete, and the probiotic composition of 0.5X, IX and 5X dosage influences little to IgG1 secretion.
Checking test 5：
Experimental group A and experiment group B are set, and wherein experimental group A is to eat the probiotic composition auxiliary treatment allergic disease
The patient of disease 20, experimental group B is the patient 20 of the starch auxiliary treatment allergic condition of edible equivalent.Once a day, every time
12g, 30 days is a course for the treatment of, continuous to use 2 courses for the treatment of.
The start recording patient of hypersensitivity illness incidence of disease and allergic condition occurring degree after 7 days are taken, and does statistical analysis.Cross
The incidence of disease reduction of quick illness, the occurring degree reduction of allergic condition are regarded as " effective ".
Referring to Fig. 9, being the probiotic composition clinical effective rate block diagram of a preferred embodiment of the present invention.Benefit is used
In the patient of raw bacteria composition, it is observed that efficient in experimental group A is 75%, experimental group B effective percentage is 40%, difference
Statistically significant (P ＜ 0.05).Prove that edible probiotic composition can effectively aid in the treatment of allergic condition.
Referring to Fig. 10, taking the allergic condition hair of Patients Before And After for the probiotic composition of a preferred embodiment of the present invention
Sick rate block diagram.Experimental group A is expressed as being not used before the probiotic composition, the incidence of disease of patient of hypersensitivity's illness；Experimental group B
It is expressed as using before the probiotic composition, the incidence of disease of patient of hypersensitivity's illness.It is observed that using the probiotic group
Compound can effectively reduce the incidence of disease of patient of hypersensitivity's illness, and difference is statistically significant (P ＜ 0.05).
Compared with prior art, the advantage of the invention is that：
The probiotic composition can effective relief of constipation；Protection and stable mucous membrane barrier, are obstructed or from enteropathogenic
The intrusion of bacterium；Prevent the possibility that intestinal cancer occurs or intestinal canal tumour grows；Stimulate and adjust intestine immunity reaction；
Wherein, sweet orange Fruit powder and hawthorn powder can promote gastrointestinal motility, reduce constipation, while being conducive to improving prebiotic
The taste of bacteria composition；
Oligoisomaltose can promote the propagation of lactobacillus and Bifidobacterium, particularly promote the propagation of Bifidobacterium,
The taste of probiotic composition can be adjusted simultaneously；
Stachyose has extremely obvious proliferation function to profitable strains such as Bifidobacterium, lactobacillus, can improve human body rapidly
Environment in alimentary canal, adjusts Tiny ecosystem colony balance.It can promote to form dominant bacteria status of the beneficial bacterium in alimentary canal, suppress
The production of the spoilage organisms such as the sour clostridium of aerogenesis production, produces a large amount of physiological activators in addition, adjusts gut pH, kills
Pathogenic bacteria, check spoilage product generation, suppress endogenous carcinogenic generation and absorption, and decomposition derives Multiple immunizations function
The factor, while stachyose band is pleasantly sweet, can adjust the taste of probiotic composition；
Dietary fiber can effectively reduce the incidences of disease such as intestinal cancer, constipation, polyposis intestinalis；
Lactobacillus and Bifidobacterium can suppress pathogenic bacteria and colonize, the organic acid such as acetic acid and lactic acid produced by newborn Bifidobacterium Bifidum
Gastric emptying can be promoted, promote intestines peristalsis, moisture in excrement is improved, reduction intestines retardance makes habitual constipation patient's defecation
Situation that is normal and relaxing constipation；Lactobacillus rhamnosus can stimulate IgA (immunoglobulin A) to secrete, increase intestine immunity protection
Ability, excludes or displacement enteric pathogenic bacteria, reduces enteric infection probability, can effectively repair impaired gut barrier；Luo Yishi bars
Bacterium can reduce the secretion of IgE (immunoglobulin E), so as to slow down the generation of allergic symptom.
Claims (6)
1. a kind of probiotic composition for being used to be good for intestines, it is characterised in that the probiotic composition includes lactobacillus, bifid bar
Bacterium, sweet orange Fruit powder, hawthorn powder, oligoisomaltose, maltodextrin, polydextrose, dietary fiber, stachyose, D-sorbite,
And physiologically acceptable excipient and/or diluent.
2. the probiotic composition as claimed in claim 1 for being used to be good for intestines, it is characterised in that the probiotic composition is included
The component of following parts by weight：100-150 parts of lactobacillus, 100-150 parts of Bifidobacteriums, 8-10 parts of oligoisomaltoses, 20-30 parts
Maltodextrin, 12-14 part polydextrose, 25-36 parts of dietary fibers, 3-7 parts of stachyoses, 4-7 parts of D-sorbites.
3. the probiotic composition as claimed in claim 1 for being used to be good for intestines, it is characterised in that the lactobacillus includes rhamnose
Lactobacillus and lactobacillus reuteri, the Bifidobacterium include bifidobacterium lactis, animal bifidobacteria and bifidobacterium breve.
4. the probiotic composition as claimed in claim 3 for being used to be good for intestines, it is characterised in that the lactobacillus includes following heavy
Measure the component of part：70-90 parts of Lactobacillus rhamnosus, 60-80 parts of lactobacillus reuteris.
5. the probiotic composition as claimed in claim 3 for being used to be good for intestines, it is characterised in that the Bifidobacterium includes following
The component of parts by weight：50-60 parts of bifidobacterium lactis, 20-30 parts of animal bifidobacterias, 5-10 parts of bifidobacterium breves.
6. being used for as any one of claim 1-5 is good for the probiotic composition of intestines, it is characterised in that the probiotics
Composition is inactivation lyophilised state.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710415773.XA CN107259576A (en) | 2017-06-02 | 2017-06-02 | Probiotic composition for being good for intestines |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710415773.XA CN107259576A (en) | 2017-06-02 | 2017-06-02 | Probiotic composition for being good for intestines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107259576A true CN107259576A (en) | 2017-10-20 |
Family
ID=60065082
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710415773.XA Pending CN107259576A (en) | 2017-06-02 | 2017-06-02 | Probiotic composition for being good for intestines |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107259576A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108041169A (en) * | 2017-11-29 | 2018-05-18 | 上海晨冠乳业有限公司 | A kind of children's solid beverage containing probiotics and prebiotics and preparation method thereof |
| CN108902517A (en) * | 2018-05-16 | 2018-11-30 | 浙江省中医药研究院 | A kind of probiotic composition and its application |
| CN110338402A (en) * | 2018-04-08 | 2019-10-18 | 王康学 | A kind of compound probiotic powder and preparation method thereof |
| CN110800906A (en) * | 2019-11-29 | 2020-02-18 | 亨美久健康科技(广东)有限公司 | Direct oral probiotic solid beverage and preparation method thereof |
| CN113768157A (en) * | 2020-06-09 | 2021-12-10 | 杭州创盈生物科技有限公司 | Active probiotic powder and preparation method thereof |
| CN113785985A (en) * | 2021-09-18 | 2021-12-14 | 中盐工程技术研究院有限公司 | Probiotic composition, preparation method and application thereof |
| WO2022268759A1 (en) * | 2021-06-22 | 2022-12-29 | Société des Produits Nestlé S.A. | Compositions and methods using a combination of at least one fiber and at least one probiotic to improve microbiome resilience |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104171798A (en) * | 2014-07-29 | 2014-12-03 | 胡安然 | Full-nutrition formula food suitable for patients with trauma, infection, operation and other stress states |
| CN106491657A (en) * | 2016-10-25 | 2017-03-15 | 广西泰和制药有限公司 | A kind of health food for strengthening regulating intestinal canal flora function and preparation method thereof |
-
2017
- 2017-06-02 CN CN201710415773.XA patent/CN107259576A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104171798A (en) * | 2014-07-29 | 2014-12-03 | 胡安然 | Full-nutrition formula food suitable for patients with trauma, infection, operation and other stress states |
| CN106491657A (en) * | 2016-10-25 | 2017-03-15 | 广西泰和制药有限公司 | A kind of health food for strengthening regulating intestinal canal flora function and preparation method thereof |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108041169A (en) * | 2017-11-29 | 2018-05-18 | 上海晨冠乳业有限公司 | A kind of children's solid beverage containing probiotics and prebiotics and preparation method thereof |
| CN110338402A (en) * | 2018-04-08 | 2019-10-18 | 王康学 | A kind of compound probiotic powder and preparation method thereof |
| CN108902517A (en) * | 2018-05-16 | 2018-11-30 | 浙江省中医药研究院 | A kind of probiotic composition and its application |
| CN110800906A (en) * | 2019-11-29 | 2020-02-18 | 亨美久健康科技(广东)有限公司 | Direct oral probiotic solid beverage and preparation method thereof |
| CN113768157A (en) * | 2020-06-09 | 2021-12-10 | 杭州创盈生物科技有限公司 | Active probiotic powder and preparation method thereof |
| WO2022268759A1 (en) * | 2021-06-22 | 2022-12-29 | Société des Produits Nestlé S.A. | Compositions and methods using a combination of at least one fiber and at least one probiotic to improve microbiome resilience |
| CN113785985A (en) * | 2021-09-18 | 2021-12-14 | 中盐工程技术研究院有限公司 | Probiotic composition, preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107259576A (en) | Probiotic composition for being good for intestines | |
| Lomax et al. | Prebiotics, immune function, infection and inflammation: a review of the evidence | |
| JP6796070B2 (en) | Foods and drinks containing indigestible components and hydrogen gas producing agents in the large intestine | |
| CN106954847A (en) | Ferment probiotic composition with function of relaxing bowel, using and process preparation | |
| CN102791849B (en) | Lactic acid bacterium-containing preparation | |
| CN103169733B (en) | Compound probiotic, application thereof for treating anaphylactic diseases and allergy free probiotic electuary for pregnant and lying-in women | |
| CN107467677A (en) | A kind of compound nutritional product for relaxing bowel, maintaining intestinal health and preparation method and application | |
| CN108477617A (en) | A kind of probiotic powder and preparation method thereof to relax bowel | |
| CN111972670A (en) | Composition for relaxing bowel, solid beverage and application | |
| AU2019241546B2 (en) | Sleep-promoting composition, and medicinal composition and food and beverage composition using said sleep-promoting composition | |
| CN101977614A (en) | Method for decreasing abdominal girth by administering a bifidobacterium bacteria | |
| CN104415060A (en) | Edible composition as well as preparation method and application thereof | |
| Faujdar et al. | Role of probiotics in human health and disease: an update | |
| CN115633717A (en) | Functional composition and application thereof in enhancing immunity and regulating intestinal flora | |
| CN106491657A (en) | A kind of health food for strengthening regulating intestinal canal flora function and preparation method thereof | |
| CN112273657A (en) | Probiotic composition for preventing or improving allergic diseases, preparation method and application | |
| CN109645501A (en) | A kind of galactooligosaccharide composition and its application of defaecation and reduction flatulence | |
| JP6261688B2 (en) | QOL improvement or persistence agent | |
| Depoorter et al. | Probiotics in pediatrics | |
| CN102917716B (en) | Immune imprinting nutritional composition | |
| Ren et al. | Safety and tolerance of Lacticaseibacillus paracasei N1115 in caesarean-born young children: a randomised, placebo-controlled trial | |
| Gupta et al. | Synbiotics: promoting gastrointestinal health | |
| CN109007842A (en) | Have effects that prevent and treat the probiotic composition of allergy and its application | |
| Kadam et al. | Probiotics and prebiotics in healthy ageing | |
| CN115104736A (en) | Breast milk oligosaccharide and probiotic composition and application thereof in promoting digestion and absorption |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20171020 |